Survival outcomes according to sFLC characteristics at end of consolidation therapy. PFS for patients with (A) normal vs elevated iFLC (median PFS, not reached and 31 months, respectively) and (B) normal vs abnormal κ:λ sFLC ratio (median PFS, not reached and 40 months, respectively). P values calculated by log-rank test. Number of patients (events) for each arm is indicated.